Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

Phase 2MP0317Positive

AI Analysis

Summary

Molecular Partners announced dosing of first patients in a Phase 2 proof-of-concept study of MP0317 combined with chemoimmunotherapy for advanced biliary tract carcinoma treatment.

Clinical Trial Data

Phase

Phase 2

Outcome Details

First patients dosed in Phase 2 proof-of-concept study

Importance:5/10

Sentiment:

0.60

Phase 2DARPin therapeuticscholangiocarcinomacombination therapyinvestigator-initiated trial

Related Companies

$MOLN

Read the original article

Published by GlobeNewswire Clinical Studies on July 16, 2026 5:00 AM

Read Original